Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomniaYahoo FinanceALLSCHWIL, SWITZERLAND - 07 July 2016 - Actelion Ltd (ATLN.VX) announced today that the company is initiating a Phase II program with its new dual orexin receptor antagonist (
